News

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...
StockStory.org on MSN19h
Why Moderna (MRNA) Stock Is Up Today
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 3.8% in the morning session after the U.S. Food and Drug ...
Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...
The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.
Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease ...
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
Labels for the Pfizer and Moderna shots, which already caution about myocarditis and pericarditis, will more strongly stress risks.
The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.
Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing the Spikevax coronavirus vaccine, was an uncharacteristically popular stock.
The SpikeVax case study Moderna’s SpikeVax vaccine is based on LNP-encapsulated nucleoside-modified mRNA encoding the full-length SARS-Cov-2 spike protein.
Moderna's new version of its COVID-19 vaccine, which targets two virus variants including Omicron, has outperformed the company's original Spikevax shot in a head-to-head clinical trial. mRNA-1273 ...